Selective in vitro effects of the farnesyl pyrophosphate synthase inhibitor risedronate on Trypanosoma cruzi

International Journal of Antimicrobial Agents

Volumn 23, Issue 3, 2004, Pages 273-285

  Garzoni, Luciana R ^a   Caldera, Aura ^b   Meirelles, Maria De Nazareth L ^a   De Castro, Solange L ^a   Docampo, Roberto ^c   Meints, Gary A ^c   Oldfield, Eric ^c   Urbina, Julio A ^b  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b INSTITUTO VENEZOLANO DE INVESTIGACIONES CIENTÍFICAS   (Venezuela)

^c UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

Amastigote; Antiproliferative effect; Chagas' disease; Risedronate; T. cruzi

Indexed keywords

ENZYME INHIBITOR; FARNESYLPYROPHOSPHATE SYNTHASE INHIBITOR; GERANYLTRANSFERASE; ISOPRENOID; PYROPHOSPHORIC ACID DERIVATIVE; RISEDRONIC ACID; STEROL; UNCLASSIFIED DRUG;

ANTIBIOTIC BIOSYNTHESIS; APICOPLAST; ARTICLE; CELL GROWTH; CELL ORGANELLE; CELL STRUCTURE; CELL VIABILITY; CHAGAS DISEASE; CONCENTRATION RESPONSE; CYTOLYSIS; DRUG EFFECT; DRUG SELECTIVITY; EPIMASTIGOTE; HOST CELL; MITOCHONDRION SWELLING; NONHUMAN; OSTEOLYSIS; PRIORITY JOURNAL; TRYPANOSOMA CRUZI;

EID: 1442336494     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2003.07.020     Document Type: Article

References (50)

1. World Health Organisation. Control of Chagas disease. Tech Rep Ser 905;2002:1-109.
2. Dias JCP. Epidemiologia. In: Brener Z, Andrade Z, Barral-Netto C, editors. Trypanosoma cruzi e doença de Chagas. Rio de Janeiro: Guanabara Koogan; 1999. p. 48-74.
3. Urbina J.A. Chemotherapy of Chagas disease. Curr Pharma Des. 8:2002;287-295.
4. Coura J.R., De Castro S.L. A critical review on Chagas disease chemotherapy. Memórias do Instituto Oswaldo Cruz. 97:2002;3-24.
5. Docampo R. Recent developments in the chemotherapy of Chagas disease. Curr Pharma Des. 7:2001;1157-1164.
6. Rodriguez J.B. Specific molecular targets to control tropical diseases. Curr Pharma Des. 7:2001;1105-1116.
7. Martin M.B., Arnold W., Heath H.T. III, Urbina J.A., Oldfield E. Nitrogen-containing bisphosphonates as carbocation transition state analogs for isoprenoid biosynthesis. Biochem Biophys Res Commun. 263:1999;754-758.
8. Bergstrom J., Bostedor D.R.G., Massarachia P.J., Reszka A.A., Rodan G.A. Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase. Arch Biochem Biophys. 373:2000;231-241.
9. Cromartie T.H., Fisher K.J., Grossman J.N. The discovery of a novel site of action for herbicidal bisphosphonates. Pest. Biochem Physiol. 63:1999;114-126.
10. Grove J.E., Brown R.J., Watts D.J. The intracellular target of the antiresorptive aminobisphosphonate drugs in Dictyostelium discoideum is the enzyme farnesyl diphosphate synthase. J Bone Mineral Res. 15:2000;971-981.
11. van Beek E., Pieterman E., Cohen L., Löwik C., Papapoulos S. Nitrogen-containing bisphosphonates inhibit isopentenyl pyrophosphate isomerase/farnesyl pyrophosphate synthase activity with relative potencies corresponding to their anti-resorptive potencies in vitro and in vivo. Biochem Biophys Res Commun. 251:1999a;491-494.
12. van Beek E., Pieterman E., Cohen L., Löwik C., Papapoulos S. Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates. Biochem Biophys Res Commun. 264:1999;108-111.
13. Montalvetti A., Bailey B.N., Martin M.B., Severin G.W., Oldfield E., Docampo R. Bisphosphonates are potent inhibitors of Trypanosoma cruzi farnesyl pyrophosphate synthase. J Biol Chem. 276:2001;33930-33937.
14. Docampo R., Moreno S.N.J. The acidocalcisome. Mol Biochem Parasitol. 33:2001;151-159.
15. Docampo R., Moreno S.N.J. Bisphosphonates as chemotherapeutic agents against trypanosomatids and Apicomplexan parasites. Curr Drug Targets-Infect Dis. 1:2001;51-61.
16. Martin M.B., Grimley J.S., Lewis J.C., Heath III H.T., Bailey B.N., Kendrick H.et al. Bisphosphonates inhibit the growth of Trypanosoma brucei, Trypanosoma cruzi, Leishmania donovani, Toxoplasma gondii and Plasmodium falciparum: a potential route to chemotherapy. J Med Chem. 44:2001;909-916.
17. Martin M.B., Sanders J.M., Kendrick H., de Luca-Fradley K., Lewis J.C., Grimley J.S.et al. Activity of bisphosphonates against Trypanosoma brucei rhodesiense. J Med Chem. 45:2002;2904-2914.
18. Rodriguez N., Bailey B.N., Martin M.B., Oldfield E., Urbina J.A., Docampo R. Radical cure of experimental cutaneous leishmaniasis by the bisphosphonate pamidronate. J Infect Dis. 186:2002;138-140.
19. Szajnman S.H., Bailey B.N., Docampo R., Rodríguez J.B. Bisphosphonates derived from fatty acids are potent growth inhibitors of Trypanosoma cruzi. Bioorg Med Chem Lett. 11:2001;789-792.
20. Yardley V., Khan A., Martin M.B., Slifer T.R., Araujo F.G., Moreno S.N.J.et al. In vivo activities of farnesyl pyrophosphate synthase inhibitors against Leishmania donovani and Toxoplasma gondii. Antimicrob Agents Chemother. 46:2002;929-931.
21. Crandall C. Risedronate: a clinical review. Arch Intern Med. 161:2001;353-360.
22. Silva L.H.P., Nussenszweig V. Sobre uma cepa de Trypanosoma cruzi virulenta para o camundongo branco. Folia Clinica Biologica. 20:1953;191-207.
23. De Maio A., Urbina J.A. Trypanosoma (Schizotrypanum) cruzi: terminal oxidases in exponential and stationary growth phase epimastigotes cultured in vitro. Acta Cientifica Venezolana. 35:1984;136-141.
24. Hudson L., Grover F., Gutteridge W.E., Klein R.A., Peters W., Neal R.A. et al. Suggested guidelines for work with live Trypanosoma cruzi. Trans. R. Soc. Trop. Med. Hyg. 77:1983;416-419.
25. Meirelles M.N., Araújo-Jorge T.C., Miranda C.F., DeSouza W., Barbosa H.S. Interaction of Trypanosoma cruzi with heart muscle cells: Ultrastructural and cytochemical analysis of endocytic vacuole formation and effect upon myogenesis in vitro. Eur. J. Cell Biol. 41:1986;198-206.
26. Urbina J.A., Lazardi K., Aguirre T., Piras M.M., Piras R. Antiproliferative synergism of the allylamine SF 86-327 and ketoconazole on epimastigotes and amastigotes of Trypanosoma (Schizotrypanum) cruzi. Antimicrob. Agents Chemother. 32:1988;1237-1242.
27. De Castro S.L., Soeiro M.N., Meirelles M.N.L. Trypanosoma cruzi: effect of phenothiazines on the parasite and its interaction with host cells. Memórias do Instituto Oswaldo Cruz. 87:1992;209-215.
28. Liendo A., Lazardi K., Urbina J.A. In vitro antiproliferative effects and mechanism of action of the bis-triazole D0870 and its S(-) enantiomer against Trypanosoma cruzi. J. Antimicrob. Chemother. 41:1998;197-205.
29. Liendo A., Visbal G., Piras M.M., Piras R., Urbina J.A. Sterol composition and biosynthesis in Trypanosoma cruzi amastigotes. Mol. Biochem. Parasitol. 104:1999;81-91.
30. Urbina J.A., Payares G., Molina J. Cure of short- and long-term experimental Chagas disease using D0870. Science. 273:1996;969-971.
31. Urbina J.A., Payares G., Contreras L.M., Liendo A., Sanoja C., Molina J.et al. Antiproliferative effects and mechanism of action of SCH 56592 against Trypanosoma (Schizotrypanum) cruzi: In vitro and in vivo studies. Antimicrob. Agents Chemother. 42:1998;1771-1777.
32. Contreras L.M., Vivas J., Urbina J.A. Altered lipid composition and enzyme activities of plasma membranes from Trypanosoma (Schizotrypanum) cruzi epimastigotes grown in the presence of sterol biosynthesis inhibitors. Biochem. Pharmacol. 53:1997;697-704.
33. Cuzner M.L., Davison A.N. Quantitative thin layer chromatography of lipids. J. Chromatogr. 27:1967;388-397.
34. Ames B., Dubin D. The role of polyamines in the neutralization of deoxyribonucleic acid. J. Biol. Chem. 235:1960;769-775.
35. Pereira M.C.S., Costa M., Chagas Filho C., Meirelles M.N.L. Myofibrillar breakdown and cytoskeletal alterations in heart muscle cells during invasion by Trypanosoma cruzi: immunological and ultrastructural study. J. Submicrosc. Cytol. Pathol. 25:1993;559-569.
36. Soares M.J. The reservosome of Trypanosoma cruzi epimastigotes: an organelle of the endocytic pathway with a role on metacyclogenesis. Memórias do Instituto Oswaldo Cruz. 94:1999;139-141.
37. Santa-Rita RM, Menna-Barreto RFS, De Castro SL. Studies with analogues of phospholipids against Trypanosoma cruzi and Leishmania amazonensis. In: Program and Abstracts of the Fifth COST-B9 Congress on Antiprotozoal Chemotherapy, London, 2002 [Abstract 25].
38. Docampo R., Moreno S.N.J., Turrens J.F., Katzin A.M., Gonzales-Cappa S.M., Stoppani A.O.M.et al. Biochemical and ultrastructural alterations produced by miconazole and ketoconazole in Trypanosoma cruzi. Mol. Biochem. Parasitol. 3:1981;169-180.
39. Lazardi K., Urbina J.A., DeSouza W. Ultrastructural alterations induced by two ergosterol biosynthesis inhibitors, ketoconazole and terbinafine, on epimastigotes and amastigotes of Trypanosoma (Schizotrypanum) cruzi. Antimicrob. Agents Chemother. 34:1990;2097-2105.
40. Lazardi K., Urbina J.A., DeSouza W. Ultrastructural alterations induced by ICI 195,739, a bis triazole with strong antiproliferative action against Trypanosoma (Schizotrypanum) cruzi. Antimicrob. Agents Chemother. 35:1991;736-740.
41. 24(25) sterol methyl transferase inhibitor, on promastigote and amastigote forms of Leishmania amazonensis. Antimicrob. Agents Chemother. 46:2002;487-499.
42. Vannier-Santos M.A., Urbina J.A., Martiny A., Neves A., DeSouza W. Alterations induced by the antifungal compounds ketoconazole and terbinafine in Leishmania. J. Eukaryotic Microbiol. 42:1995;337-346.
43. 24(25) sterol methyl transferase inhibitors and their combinations with ketoconazole. Int. J. Antimicrob. Agents. 7:1996;235-240.
44. Rodrigues C.O., Catisti R., Uyemura S.A., Vercesi A.E., Lira R., Rodriguez C.et al. The sterol composition of Trypanosoma cruzi changes after growth in different culture media and results in different sensitivity to digitonin-permeabilization. J. Eukaryot. Microbiol. 48:2001;588-594.
45. Engel J.C., Doyle P.S., Palmer J., Hsieh I., McKerrow J.H. Cysteine protease inhibitors alter Golgi complex ultrastructure and function in Trypanosoma cruzi. J Cell Sci. 111:1998;597-606.
46. Rodan G.A. Mechanisms of action of bisphosphonates. Annu Rev Pharmacol Toxicol. 38:1998;375-388.
47. Rodan G.A., Martin T.J. Therapeutic approaches to bone diseases. Science. 289:2000;1508-1514.
48. Urbina J.A., Moreno B., Vierkotter S., Oldfield E., Payares G., Sanoja C.et al. Trypanosoma cruzi contains major pyrophosphate stores, and its growth in vitro and in vivo is blocked by pyrophosphate analogues. J Biol Chem. 274:1999;33609-33615.
49. Lin Z.X., Holtzer S., Schultheiss T., Murray J., Masaki T., Fischman D.A.et al. Polygons and adhesion plaques and disassembly and assembly of myofibrils in cardiac myocytes. J Cell Biol. 108:1989;2355-2367.
50. Garzoni LR, Caldera A, Meirelles MNL, de Castro SL, Docampo R, Meints GA, et al. Antiparasitic activity of risedronate in a murine model of acute Chagas disease. Int J Antimicrob Agents 2004;23:286-90.